

Access DB# 80467

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: _____ Examiner #: _____ Date: _____
Art Unit: _____ Phone Number 30 _____ Serial Number: _____
Mail Box and Bldg/Room Location: _____ Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: _____

Inventors (please provide full names): _____

Earliest Priority Filing Date: _____

**For Sequence Searches Only* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*

Jan Delaval
Reference Librarian
Biotechnology & Chemical Library
CM1 1E07 - 703-308-4498
jan.delaval@uspto.gov

STAFF USE ONLY

	Type of Search	Vendors and cost where applicable
Searcher: <u>Jan</u>	NA Sequence (#) _____	STN _____
Searcher Phone #: <u>4498</u>	AA Sequence (#) <u>✓</u>	Dialog _____
Searcher Location: _____	Structure (#) _____	Questel/Orbit _____
Date Searcher Picked Up: <u>11/18/02</u>	Bibliographic _____	Dr.Link _____
Date Completed: <u>11/18/02</u>	Litigation _____	Lexis/Nexis _____
Searcher Prep & Review Time: _____	Fulltext _____	Sequence Systems <u>✓</u>
Clerical Prep Time: <u>15</u>	Patent Family _____	WWW/Internet _____
Online Time: <u>4 10</u>	Other _____	Other (specify) _____

Set	Items	Description
S1	237	(CD30L OR CD30(W)LIGAND) AND (TUMOR? OR CANCER? OR TUMOUR?)
S2	22	(CD30L OR CD30(W)LIGAND) AND (TREAT? OR THERAP? OR INHIBIT? OR SUPPRESS? OR PREVENT?) (10N) (TUMOR? OR CANCER? OR TUMOUR?)
S3	15	RD S2 (unique items)
S4	106	(CD30L OR CD30(W)LIGAND) (20N) (TUMOR? OR CANCER? OR TUMOU- R?)
S5	51	RD S4 (unique items)
S6	3	(CD40L OR CD40(W)LIGAND OR CD30L OR CD30(W)LIGAND) AND PHO- TODYNAMIC
S7	3	RD S6 (unique items)
S8	729	PHOTODYNAMIC (20N) (COMBINATION OR COMBINED)
S9	740	PHOTODYNAMIC (20N) (COMBINATION OR COMBINED) (10N) (THERAP? OR TREAT?)
S10	6	PHOTODYNAMIC (20N) (COMBINATION OR COMBINED) (10N) (THERAP? OR TREAT?) (10N) (CYTOKINE? OR LYMPHOKINE?)
S11	3	RD S10 (unique items)

ds

Set	Items	Description
S1	237	(CD30L OR CD30(W)LIGAND) AND (TUMOR? OR CANCER? OR TUMOUR?)
S2	22	(CD30L OR CD30(W)LIGAND) AND (TREAT? OR THERAP? OR INHIBIT? OR SUPPRESS? OR PREVENT?)(10N) (TUMOR? OR CANCER? OR TUMOUR?)
S3	15	RD S2 (unique items)

? t s3/3/all

3/3/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

13591306 BIOSIS NO.: 200200220127
Differential activity of TRAIL/Apo-2L in Hodgkin disease (HD) and CD30+ lymphoid cell lines is independent of CD30 activation.
AUTHOR: Fiumara Paolo(a); Snell Virginia(a); Li Yang(a); Mukhopadhyay Asok(a); Younes Mamoun; Andreeff Michael(a); Cabanillas Fernando(a); Carbone Antonino; Aggarwal Bharat(a); Younes Anas(a)
AUTHOR ADDRESS: (a)M. D. Anderson Cancer Center, Houston, TX**USA
JOURNAL: Blood 98 (11 Part 1):p599a November 16, 2001
MEDIUM: print
CONFERENCE/MEETING: 43rd Annual Meeting of the American Society of Hematology, Part 1 Orlando, Florida, USA December 07-11, 2001
ISSN: 0006-4971
RECORD TYPE: Abstract
LANGUAGE: English

3/3/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

13112983 BIOSIS NO.: 200100320132
A pilot study of rituximab in patients with relapsed Hodgkin's disease of classical type.
AUTHOR: Younes A(a); Romaguera J(a); Hagemeister F(a); Rodriguez M(a); McLaughlin P(a); Medeiros J(a); Cabanillas F(a)
AUTHOR ADDRESS: (a)U.T. M.D. Anderson Cancer Center, Houston, TX**USA
JOURNAL: Blood 96 (11 Part 1):p733a November 16, 2000
MEDIUM: print
CONFERENCE/MEETING: 42nd Annual Meeting of the American Society of Hematology San Francisco, California, USA December 01-05, 2000
SPONSOR: American Society of Hematology
ISSN: 0006-4971
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

3/3/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

13057538 BIOSIS NO.: 200100264687
Chronic lymphocytic leukemia B cells impair immunoglobulin class switching by inducing CD30+ suppressor T cells.
AUTHOR: Cerutti Andrea(a); Kim Edmund C(a); Zan Hong(a); Schaffer Andras(a); Casali Paolo(a)
AUTHOR ADDRESS: (a)Weill Medical College of Cornell University, 1300 York Avenue, New York, NY, 10021**USA
JOURNAL: FASEB Journal 15 (5):pA1202 March 8, 2001
MEDIUM: print
CONFERENCE/MEETING: Annual Meeting of the Federation of American Societies

for Experimental Biology on Experimental Biology 2001 Orlando, Florida,
USA March 31-April 04, 2001
ISSN: 0892-6638
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

3/3/4 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

12872612 BIOSIS NO.: 200100079761
Distinct effects of CD30 and Fas signaling in cutaneous anaplastic
lymphomas: A possible mechanism for disease progression.
AUTHOR: Levi Edi; Wang Zhenxi; Petrogiannis-Haliotis Tina; Pfeifer Walther
M; Kempf Werner; Drews Reed; Kadin Marshall E(a)
AUTHOR ADDRESS: (a)Department of Pathology, YA 309, Beth Israel-Deaconess
Medical Center, 330 Brookline Avenue, Boston, MA, 02215:
mkadin@caregroup.harvard.edu**USA
JOURNAL: Journal of Investigative Dermatology 115 (6):p1034-1040 December,
2000
MEDIUM: print
ISSN: 0022-202X
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

3/3/5 (Item 5 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

09719345 BIOSIS NO.: 199598174263
Shedding of the soluble form of CD30 from the Hodgkin-analogous cell line
L540 is strongly inhibited by a new CD30-specific antibody (Ki-4).
AUTHOR: Horn-Lohrens Ottmar; Tiemann Markus; Lange Hans; Kobarg Jorg;
Hafner Martin; Hansen Hinrich; Sterry Wolfram; Parwaresch Reza M; Lemke
Hilmar
AUTHOR ADDRESS: Biochemisches Inst. der Christian-Albrechts, Univ. zu
Kiel, D-24118 Kiel 1, Olshausenstr. 40**Germany
JOURNAL: International Journal of Cancer 60 (4):p539-544 1995
ISSN: 0020-7136
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

3/3/6 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2002 Elsevier Science B.V. All rts. reserv.

11449616 EMBASE No: 2002021386
Expression of CD40 ligand (CD154) in B and T lymphocytes of Hodgkin
disease: Potential therapeutic significance
Clodi K.; Asgari Z.; Younes M.; Palmer J.L.; Cabanillas F.; Carbone A.;
Andreeff M.; Younes A.
Dr. A. Younes, Department of Lymphoma/Myeloma, University of Texas, M. D.
Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030
United States
AUTHOR EMAIL: ayounes@notes.mdacc.tmc.edu
Cancer (CANCER) (United States) 01 JAN 2002, 94/1 (1-5)
CODEN: CANCA ISSN: 0008-543X

DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 20

3/3/7 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2002 Elsevier Science B.V. All rts. reserv.

11431982 EMBASE No: 2002003606
Human angiogenin fused to human **CD30 ligand** (Ang-CD30L)
exhibits specific cytotoxicity against CD30-positive lymphoma
Huhn M.; Sasse S.; Tur M.K.; Matthey B.; Schinkothe T.; Rybak S.M.; Barth
S.; Engert A.
S. Barth, Fraunhofer IME, Dept. of Pharmaceut. Product Devmt., Worringer
Weg 1, 52074 Aachen Germany
AUTHOR EMAIL: barth@ime.fhg.de
Cancer Research (CANCER RES.) (United States) 15 DEC 2001, 61/24
(8737-8742)
CODEN: CNREA ISSN: 0008-5472
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 43

3/3/8 (Item 3 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2002 Elsevier Science B.V. All rts. reserv.

11337351 EMBASE No: 2001352177
Progression of lymphomatoid papulosis to systemic lymphoma is associated
with escape from growth inhibition by transforming growth factor-beta and
CD30 ligand
Kadin M.E.; Levi E.; Kempf W.
Dr. M.E. Kadin, Laboratory Medicine, Beth Israel Deaconess Med. Center,
330 Brookline Ave., Boston, MA 02215 United States
AUTHOR EMAIL: mkadin@caregroup.harvard.edu
Annals of the New York Academy of Sciences (ANN. NEW YORK ACAD. SCI.) (
United States) 2001, 941/- (59-68)
CODEN: ANYAA ISSN: 0077-8923
DOCUMENT TYPE: Journal ; Conference Paper
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 30

3/3/9 (Item 4 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2002 Elsevier Science B.V. All rts. reserv.

10785306 EMBASE No: 2000263717
Autocrine growth regulation of **CD30 ligand** in CD30-
expressing Reed-Sternberg cells: Distinction between Hodgkin's disease and
anaplastic large cell lymphoma
Hsu P.-L.; Hsu S.-M.
Dr. S.-M. Hsu, Department of Pathology, Natl. Taiwan Univ. Coll. of
Medicine, 7 Chun-Shun S Road, Taipei 10016 Taiwan
AUTHOR EMAIL: smhsu@ha.mc.ntu.edu.tw
Laboratory Investigation (LAB. INVEST.) (United States) 2000, 80/7
(1111-1119)
CODEN: LAINA ISSN: 0023-6837
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 50

3/3/10 (Item 5 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2002 Elsevier Science B.V. All rts. reserv.

10602349 EMBASE No: 2000067635
Tissue eosinophilia correlates strongly with poor prognosis in nodular sclerosing Hodgkin's disease, allowing for known prognostic factors
Von Wasielewski R.; Seth S.; Franklin J.; Fischer R.; Hubner K.; Hansmann M.L.; Diehl V.; Georgii A.
Dr. R. Von Wasielewski, Institut fur Pathologie, Medizinische Hochschule Hannover, Carl - Neuberg Strasse 1, D-30625 Hannover Germany
AUTHOR EMAIL: wasielewski.reinhard.von@mh-hannover.de
Blood (BLOOD) (United States) 15 FEB 2000, 95/4 (1207-1213)
CODEN: BLOOA ISSN: 0006-4971
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 62

3/3/11 (Item 6 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2002 Elsevier Science B.V. All rts. reserv.

07928709 EMBASE No: 1999402580
Constitutive expression and role of the TNF family ligands in apoptotic killing of tumor cells by human NK cells
Kashii Y.; Giorda R.; Herberman R.B.; Whiteside T.L.; Vujanovic N.L.
Dr. N.L. Vujanovic, University of Pittsburgh, Cancer Institute, Biomedical Science Tower W1045, 211 Lothrop Street, Pittsburgh, PA 15213 United States
AUTHOR EMAIL: vujanovicnl@msx.upmc.edu
Journal of Immunology (J. IMMUNOL.) (United States) 15 NOV 1999, 163/10 (5358-5366)
CODEN: JOIMA ISSN: 0022-1767
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 37

3/3/12 (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

09867477 98283419 PMID: 9622100
Enhancement of antitumor immunity by expression of CD70 (CD27 ligand) or CD154 (CD40 ligand) costimulatory molecules in tumor cells.
Couderc B; Zitvogel L; Douin-Echinard V; Djennane L; Tahara H; Favre G; Lotze M T; Robbins P D
Department of Molecular Genetics and Biochemistry, University of Pittsburgh School of Medicine, Pennsylvania 15261, USA.
Cancer gene therapy (UNITED STATES) May-Jun 1998, 5 (3) p163-75,
ISSN 0929-1903 Journal Code: 9432230
Contract/Grant No.: CA59371; CA; NCI
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

3/3/13 (Item 2 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

09766051 98189269 PMID: 9514701
CD30-regulated apoptosis in murine CD8 T cells after cessation of TCR

signals.

Telford W G; Nam S Y; Podack E R; Miller R A
Department of Pathology, University of Michigan Medical School, Ann Arbor, USA.

Cellular immunology (UNITED STATES) Dec 15 1997, 182 (2) p125-36,
ISSN 0008-8749 Journal Code: 1246405

Contract/Grant No.: AG03978; AG; NIA; AG08808; AG; NIA; AG09801; AG; NIA;

+

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

3/3/14 (Item 1 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2002 American Chemical Society. All rts. reserv.

136182462 CA: 136(12)182462j PATENT

Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L

INVENTOR(AUTHOR): Mohler, Kendall M.; Barone, Dauphine S.; Peschon, Jacques J.; Kennedy, Mary K.; Pluenneke, John D.

LOCATION: USA

ASSIGNEE: Immunex Corporation

PATENT: PCT International ; WO 200211767 A2 DATE: 20020214

APPLICATION: WO 2001US24783 (20010806) *US PV224079 (20000808)

PAGES: 76 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-047/00A

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

3/3/15 (Item 2 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2002 American Chemical Society. All rts. reserv.

133191263 CA: 133(14)191263k JOURNAL

Analysis of TNF-receptor and ligand superfamily molecules in patients with lymphoproliferative disease of granular lymphocytes

AUTHOR(S): Zambello, Renato; Trentin, Livio; Facco, Monica; Siviero, Marta; Galvan, Silvia; Piazza, Francesco; Perin, Alessandra; Agostini, Carlo; Semenzato, Gianpietro

LOCATION: Division of Hematology, Vicenza Hospital, Vicenza, Italy

JOURNAL: Blood DATE: 2000 VOLUME: 96 NUMBER: 2 PAGES: 647-654

CODEN: BLOOAW ISSN: 0006-4971 LANGUAGE: English PUBLISHER: American Society of Hematology

?